NCT06422806: Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas |
|
|
| Recruiting | 3 | 180 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging, Medical Imaging, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475 | National Cancer Institute (NCI) | Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Undifferentiated Pleomorphic Sarcoma | 06/26 | 06/26 | | |
NCT03957551: Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma |
|
|
| Active, not recruiting | 1/2 | 28 | US | Cabozantinib, XL184, COMETRIQ™, Cabometyx®, Pembrolizumab, Keytruda | John Rieth, Exelixis, University of Iowa | Advanced Metastatic Melanoma | 06/24 | 12/26 | | |
NCT04634227: Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) |
|
|
| Recruiting | 1 | 40 | US | Ascorbate | University of Iowa, Mohammed Milhem, MBBS | Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma | 08/25 | 08/25 | | |
